Is “Leaky Gut” Real? What the Science Actually Says About Intestinal Permeability

Every so often a thoughtful clinician — someone rigorous, well-read, and rightly skeptical — will pause on the phrase “leaky gut” and ask the fair question: is this actually real, or is it functional-medicine folklore? It is one of the best questions in the field, and it deserves a careful answer rather than a slogan. This article is written in that spirit — not to win an argument, but to revisit the concept honestly, with the current science in hand.

Part of what makes the question worth asking is that the term gets used in two very different ways. In some circles “leaky gut” is invoked as the hidden cause of nearly every ailment; in others it is dismissed as pseudoscience. Neither reflects what the literature actually shows — and the space in between is where the interesting, useful medicine lives.

“The intestinal barrier is real. Increased intestinal permeability is real, measurable, and documented across many human diseases. What’s not established is that every symptom people blame on it truly comes from it — or that one blood or stool marker can diagnose it.”

The most scientifically accurate conclusion is neither “leaky gut explains everything” nor “leaky gut is imaginary.” It is that intestinal barrier dysfunction is an important biological process whose clinical significance varies substantially from one disease and one patient to the next. This article walks through the evidence honestly — the strong parts and the shaky parts — and then to the practical question our patients actually care about: when the barrier is compromised, how do we help it heal?

What Is the Intestinal Barrier?

The intestine has a genuinely difficult job. It must absorb water, electrolytes, fats, amino acids, vitamins, and carbohydrates while keeping out microbes, microbial fragments, toxins, and half-digested food antigens. It does this across a surface roughly the size of a studio apartment, separated from your bloodstream by a lining just one cell thick.

This barrier is not a simple wall. It is a layered, living system that includes:

• The mucus layer and its antimicrobial peptides
• A single layer of intestinal epithelial cells
• Tight junctions sealing the space between those cells
• Secretory IgA and resident mucosal immune cells
• The gut microbiome living above the mucus
• The blood and lymphatic vessels just beneath the lining

Tight junctions are built from proteins with names like claudins, occludin, junctional adhesion molecules, and zonula occludens (ZO) proteins.¹ They are not glue; they are dynamic gates. Crucially, permeability is not all-or-nothing. A healthy barrier is selective and constantly adjusting — some small molecules are supposed to cross.

Modern research distinguishes several pathways: a highly selective “pore” pathway for small ions, a less selective “leak” pathway that can let larger molecules through, and, with real epithelial damage, an “unrestricted” pathway.³ Lumping all of these together as “leaky gut” blurs important biology — a distinction that matters when we talk about testing and treatment later.

Is Increased Intestinal Permeability Scientifically Established?

Yes — unambiguously. This is the part skeptics sometimes miss. Abnormal intestinal permeability has been demonstrated with a range of objective tools: urinary multi-sugar absorption tests (lactulose–mannitol or lactulose–rhamnose ratios),⁴ ex vivo Ussing-chamber measurements, confocal laser endomicroscopy, transepithelial electrical resistance, direct analysis of tight-junction proteins, and measurement of microbial translocation products in research settings.

The phenomenon is especially well established in celiac disease, Crohn’s disease, ulcerative colitis, graft-versus-host disease, severe infection, critical illness, burns, shock, and some liver diseases. In Crohn’s, increased permeability appears not only in inflamed segments but in apparently normal bowel and in some healthy first-degree relatives. A landmark prospective study found that increased permeability can precede the diagnosis of Crohn’s by years in at-risk people.¹² That timing matters: barrier dysfunction is not always merely a consequence of visible inflammation.

Barrier integrity also carries prognostic weight. In inflammatory bowel disease, evidence of barrier healing has predicted relapse and major outcomes — in one prospective trial outperforming standard endoscopic and histologic remission.¹³

So the useful questions are sharper than “is it real?” They are: In which diseases is permeability a central driver? Where is it an amplifier or a bystander? Can we measure it accurately in ordinary practice? And does fixing it change outcomes for a given patient?

Cause, Consequence, or Vicious Cycle?

This is the real controversy. Inflammation can loosen tight junctions: cytokines such as TNF, interferon-gamma, and IL-1 alter cytoskeletal signaling and junction regulation.² Epithelial injury can also come from infection, ischemia, medications, alcohol, bile acids, microbial metabolites, or immune attack. Once the barrier is more permeable, microbial products and food antigens reach the immune cells beneath the lining more easily, which drives more inflammation:

This feedback loop is highly plausible and well supported experimentally. But demonstrating a loop does not tell us which event started the illness in a specific person. In Crohn’s disease, genetic susceptibility, immune dysregulation, microbiome shifts, environmental triggers, and barrier dysfunction all interact — it would be simplistic to crown any one of them the sole cause. The same caution applies, even more strongly, to metabolic, neurological, and generalized autoimmune conditions: association is important, but association alone does not prove that restoring permeability will reverse a disease.

That is exactly the tension a thoughtful clinician has to hold: take the barrier seriously without turning it into a theory of everything.

The Microbiome & Dysbiosis: Where the Inflammation Often Starts

You cannot talk honestly about the gut barrier without talking about the community living on top of it. The microbiome helps train the immune system, produces protective metabolites, competes with pathogens, and directly nourishes the lining. When that community drifts out of balance — dysbiosis — the consequences ripple outward.

One of the clearest mechanistic threads runs through short-chain fatty acids (SCFAs), especially butyrate. Butyrate is the preferred fuel of the colonocytes that line the large intestine, and it helps assemble tight junctions through AMPK signaling.³⁵ Patients with IBS and related conditions frequently show reduced butyrate-producing bacteria and altered SCFA profiles.³⁶ In other words, dysbiosis can quietly starve the gut lining of the very fuel it needs to stay sealed.

Dysbiosis and overgrowth also raise the body’s inflammatory tone directly. Bacterial fragments such as lipopolysaccharide (LPS) that cross a compromised barrier can trigger low-grade systemic inflammation — a state researchers named “metabolic endotoxemia” and linked to insulin resistance and obesity.³² This is the plausible bridge between a struggling gut and inflammation felt everywhere else — and, as we’ll see, a likely on-ramp to autoimmunity.

SIBO, IMO, and Intestinal Permeability

Small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO, the methane-predominant picture) often coexist with barrier dysfunction — but they are not interchangeable with it. Overgrowth increases fermentation, gas, altered bile-acid metabolism, mucosal irritation, and exposure to microbial metabolites. In turn, impaired motility, low stomach acid, anatomical changes, medications, and immune disturbances all favor overgrowth. Another loop:

Two honest caveats. First, evidence that every patient with elevated methane has clinically important macromolecular permeability is lacking — methane is more directly tied to slowed transit and constipation than to a universal “leaky” state.⁴⁶ Second, breath testing is imperfect, with meaningful false positives and negatives, which is why we treat it as one input rather than a verdict.⁴⁷

Dietary tools like low-FODMAP reduce fermentable substrate and genuinely help symptoms in many patients — but they work best as a structured, temporary phase (several weeks of restriction, then systematic reintroduction and personalization), not permanent, indiscriminate restriction.⁴⁵ One common and understandable mistake is trying FODMAPs half-heartedly — a few days here and there — and concluding it “doesn’t work.” The structured protocol exists precisely to avoid that trap. We say more about the diet question — and why it’s such a revealing clue — further below.

Alcohol, NSAIDs, and the Everyday Insults

Some barrier stressors are hiding in plain sight. Alcohol is a well-documented one: ethanol and its metabolite acetaldehyde can disrupt tight-junction proteins, raise oxidative stress, shift the microbiome, and promote translocation of microbial products — effects clearly demonstrated in models and in alcohol-associated liver disease.¹⁶ Does a nightly glass or two of wine automatically cause SIBO or autoimmunity? No — the dose–response at modest intake is genuinely uncertain, and we shouldn’t overclaim. But in a patient with stubborn overgrowth, bloating, reflux, poor sleep, or suspected barrier trouble, a four-to-six-week alcohol-free trial is a reasonable experiment. Its value is in watching that individual’s response, not in declaring alcohol guilty in advance.

NSAIDs (ibuprofen, naproxen, and relatives) reliably increase small-intestinal permeability and can injure the lining — one of the better-established pharmacologic causes.¹⁷ Other contributors with real mechanistic support include gastrointestinal infection, chronic psychological and physiological stress, hyperglycemia and metabolic disease, bile-acid disturbances, dysbiosis, malnutrition, intense endurance exercise, and disrupted sleep.

Why Now? The Modern Assault on an Ancient Ecosystem

Here is a question that ought to give every clinician pause. If barrier dysfunction and its downstream conditions were rare a century ago and are common now, something in the environment must have changed — because our genes have not. And when we look at the trend lines for the diseases most plausibly linked to a disordered gut, they are not drifting upward. They are climbing steeply.

Food allergies are a case in point. Food allergy now affects roughly 1 in 10 US adults,⁵³ and a growing body of work — captured in the epithelial barrier hypothesis — argues that damage to our barriers (gut, skin, airway) is a central driver of the modern rise in allergic and autoimmune disease.⁷⁸ Impaired intestinal barrier function is specifically associated with food allergy: when the barrier leaks, the immune system samples food proteins it was meant to tolerate, and sensitization can follow.⁷⁹ This reframes a great deal of what gets labeled “food allergy.” It helps explain why so many patients react to more and more foods over time — and why, when we heal the barrier and remove the biggest triggers, that list of “problem foods” so often shrinks. (More on that in the diet section below.)

What changed? In a single lifetime we have introduced a series of unprecedented insults to a microbial ecosystem that co-evolved with us over hundreds of thousands of years:

• Antibiotic overuse. Even one course perturbs the microbial community, and some effects are long-lasting.⁵⁶ Antibiotic exposure in the first two years of life is associated with higher later rates of asthma, allergy, atopic dermatitis, celiac disease, and obesity.⁵⁷
• The decline of vaginal birth and breastfeeding. Cesarean delivery — now about one in three US births — changes how the infant microbiome is first seeded,⁵⁸ and human milk delivers oligosaccharides that feed and train that microbiome in ways formula cannot fully replicate.⁵⁹
• Glyphosate in the food supply. The world’s most-used herbicide targets the shikimate pathway — a pathway absent in human cells but present in a large share of our gut bacteria, making much of the microbiome potentially susceptible.⁶⁰ (Real-world human health impact is still debated; we present it as a plausible mechanism, not a settled verdict. See our article on glyphosate as a pervasive toxin.)
• Low-grade antibiotic exposure through food. The majority of antibiotics produced globally are used in food-animal production, not human medicine⁶¹ — a continuous, low-dose background exposure via conventionally raised meat and poultry.

This is where leaky gut stops being an abstract debate and becomes a story about how we live. A barrier that depends on a healthy, well-fed microbial community is being asked to hold the line against antibiotics, a stripped-down diet, herbicide residues, chronic stress, and a food supply engineered for shelf life rather than for our microbes. Viewed this way, rising rates of allergy, IBS, and autoimmunity are not a mystery — they are close to what we should expect. Our full take is in why maintaining your microbiome is critical to your health.

The Mold Connection: Biotoxins, Low MSH, and a Leaky Barrier

If there is a single driver of stubborn leaky gut and autoimmunity that mainstream evaluations miss most often, it is ongoing mold and biotoxin exposure from a water-damaged building. In our practice it is one of the most important root causes we find — and one of the reasons a patient can do everything “right” for their gut and still not heal. Mold injures the barrier through two distinct mechanisms, one direct and one hormonal.

The direct route is straightforward toxicology. Mold produces mycotoxins, and mycotoxins are hard on the intestinal lining. Deoxynivalenol and related trichothecenes measurably reduce tight-junction proteins such as claudins, lower transepithelial resistance, and increase permeability,⁷⁰ and reviews of the broader mycotoxin family — ochratoxin A, aflatoxin, fumonisins — describe the same pattern of damage to the epithelial barrier, the mucus layer, and the microbiome.⁷¹ A mold-exposed patient is, quite literally, ingesting barrier-disrupting compounds.

The hormonal route is subtler and, in our experience, more far-reaching. Chronic biotoxin exposure suppresses a small but powerful regulatory hormone called MSH (melanocyte-stimulating hormone) — a hallmark of what is described clinically as Chronic Inflammatory Response Syndrome (CIRS).⁷⁴ MSH is a master regulator of mucosal defense, and its active fragment, alpha-MSH, directly protects the intestinal barrier: in laboratory models it shields tight junctions from the very inflammatory cytokines (TNF and interferon-gamma) that drive leaky gut,⁷² and the wider melanocortin system is broadly anti-inflammatory in the gut.⁷³ When mold drives MSH down, the barrier loses one of its key protective signals — and permeability, malabsorption, and dysregulated mucosal immunity tend to follow.

Low MSH does something else, too: it opens the door to MARCoNS (a multi-antibiotic-resistant staph that colonizes the deep sinuses), which then perpetuates the inflammatory loop and keeps MSH suppressed. Clearing MARCoNS has been associated with rising alpha-MSH,⁷⁵ which is one reason these problems travel together and why the gut so often fails to heal until the biotoxin source is addressed. We cover that whole cycle in depth in Why Won’t My MARCoNS Clear?

Hidden Dental Infections: The Other Silent Driver

If mold is the environmental driver clinicians miss most, hidden dental infections are a close second — and in our experience they are a recurring, under-appreciated contributor to leaky gut, SIBO, and irritable bowel syndrome. The usual suspects are cavitations (chronically infected or poorly healed jawbone sites, classically old wisdom-tooth extraction sockets), infected root-canal-treated teeth, and the ongoing burden of mercury from “silver” amalgam fillings. Each represents a quiet, low-grade source of infection, inflammation, or toxic load that the body must contend with day after day.

How could a problem in the mouth reach the gut? The oral–gut axis is real and increasingly well documented. In a landmark study, oral bacteria that reached and colonized the intestine were shown to drive inflammatory TH1 immune responses — a direct mechanistic link between the mouth’s microbial community and gut inflammation.⁷⁶ We swallow billions of oral organisms daily; when the oral terrain is disordered by chronic infection, that seeding matters. Mercury adds a second layer: experimental work found that mercury released from amalgam fillings increased mercury- and antibiotic-resistant bacteria in the oral and intestinal flora,⁷⁷ a reminder that heavy metals can reshape the microbiome (though the human clinical significance remains debated).

One group of organisms we watch closely is the periodontal “red complex” — Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola — the cluster most strongly tied to gum disease.⁸⁴ We are finding these red-complex bacteria in a striking number of our patients, and the research on the ringleader, P. gingivalis, is provocative: when swallowed, it has been shown to alter the gut microbiome, drive systemic inflammation,⁸⁵ and impair the intestinal barrier enough to let gut bacteria translocate to the liver — at least in animal models.⁸⁶ The oral cavity, in other words, may be an upstream source of the very dysbiosis and permeability we are trying to treat downstream. It is one more reason we screen the mouth when the gut won’t cooperate.

We explore this whole territory in depth elsewhere: our Dental & Chronic Health Challenges webinar, our article on infected root canals as a hidden root cause, and our overview of oral health as the gateway to overall wellness. The theme that unites mold and teeth is the same one that runs through this entire article: a barrier under chronic assault cannot heal until the source of the assault is found and removed.

Stress, Cortisol, and the Nervous System

Of all the drivers of leaky gut, stress is the one patients most often dismiss — and the one with some of the cleanest human evidence. In a controlled crossover study in healthy volunteers, acute psychological stress (and the stress hormone CRH) measurably increased small-intestinal permeability, and the effect was blocked by a mast-cell stabilizer — showing a direct, causal path from the stressed brain to a leakier gut.⁸⁰ Chronic stress compounds this through cortisol and the broader gut–brain axis, degrading the barrier and reshaping the microbiome over time.⁸¹

The downstream cascade is where it gets clinically important. Sustained stress and elevated cortisol promote insulin resistance (a barrier stressor in its own right), slow intestinal motility — a setup for SIBO — and tip the autonomic nervous system into a sympathetic-dominant, “fight-or-flight” state that is the opposite of the “rest-and-digest” mode the gut needs to repair.

The overtraining trap: when “healthy” becomes a stressor

Stress isn’t only emotional — it can be physical, and here even fitness-minded people get caught. A meaningful subset of our patients simply overdo it: training hard every single day with no real rest or recovery. That relentless load is a chronic physiological stressor, and intense endurance exercise is one of the best-documented causes of transient leaky gut — the “exercise-induced gastrointestinal syndrome,” in which prolonged exertion shunts blood away from the gut and measurably increases intestinal permeability.⁸⁷

I know this one personally. When I competed in long races — 50K and up, marathon distance and beyond — I would reliably finish with severe bloating, indigestion, and acid reflux. My gut was paying the price for the effort, and I have no doubt I carried a degree of leaky gut for a stretch after each of those events. Most people never push to that extreme — but the lesson scales down: chronic, low-grade barrier stress from overtraining and never truly resting is real, and it is easy to miss precisely because the person doing it believes they’re being healthy. The body keeps score; it pays to listen.

Could This Be You? Symptoms and Associated Conditions

Because the gut barrier touches immunity, inflammation, and nutrient status, the fingerprints of barrier dysfunction rarely stay in the abdomen. Here the story becomes personal for many people — and here is where conventional primary care most often looks past the likeliest explanation. When a patient presents with fatigue, rashes, or aches, the first questions are rarely about the gut, food, or the barrier — even though those may be the most common and most modifiable drivers of all.

Symptoms that can point toward barrier dysfunction

None of these proves leaky gut — but a cluster of them, especially with a known trigger (a course of antibiotics, a stressful season, mold exposure, a gut infection), is worth taking seriously:

• Digestive: bloating, gas, reflux, loose stools or constipation, and reacting to more and more foods
• Systemic: fatigue, brain fog, low mood or anxiety, and unrefreshing sleep
• Inflammatory: joint aches, muscle pain, and generalized “inflamed” feeling
• Skin: eczema, hives, rosacea, and stubborn rashes (see below)
• Immune / nutritional: frequent infections, new food sensitivities, and low iron, B12, or vitamin D despite a reasonable diet

The gut–skin connection

Skin deserves special mention because it is so often missed. The gut–skin axis is well described: gut dysbiosis and barrier dysfunction are linked to eczema, psoriasis, acne, and rosacea,⁸² and increased intestinal permeability has been documented in patients with atopic eczema for decades.⁸³ Yet a person can present with a skin eruption, receive a biopsy and a label of “contact dermatitis,” and never once be asked about food, the gut, or recent exposures. We have watched this happen to people close to us — a negative biopsy, an assumption of contact dermatitis, and no one connecting it to diet at all. It is a small, everyday example of a much larger blind spot.

The bottom line: conventional primary care rarely looks first at the most prevalent, most modifiable driver of all — the gut barrier and the foods crossing it.

The Autoimmune Connection — Strongest Where the Antigen Is Known

This is where leaky gut becomes clinically compelling, and also where discipline matters most. The barrier has been investigated in type 1 diabetes, rheumatoid arthritis, multiple sclerosis, autoimmune liver and thyroid disease, ankylosing spondylitis, lupus, and celiac disease. Several lines of evidence support a real contribution: barrier abnormalities sometimes precede disease; microbial products activate innate immunity; increased permeability raises antigen exposure; some microbes promote molecular mimicry or bystander activation; and barrier-directed interventions improve disease in animal models. (For a broader overview, see our companion article on the growing threat of autoimmune disease.)

Celiac disease: the clearest model

Celiac is the cleanest example of a dietary antigen, genetic susceptibility, immune activation, and altered permeability all interacting. In susceptible people, gluten-derived peptides trigger an adaptive immune response, and gliadin also stimulates zonulin release and tight-junction loosening.⁷ A gluten-free diet improves both inflammation and barrier function in most patients. Celiac proves that a food antigen can drive immune-mediated intestinal disease — but it does not prove that gluten or “plant foods” disrupt the barrier in everyone.

From the gut to the whole body

Beyond celiac, the evidence is real but more mechanistic. Increased permeability has been reported before the clinical onset of type 1 diabetes,¹⁹ fitting the “perfect storm” model of microbiota, permeability, and mucosal immunity converging.²⁰ In a striking series of experiments, translocation of a single gut bacterium (Enterococcus gallinarum) beyond the barrier was shown to drive autoimmunity in mouse models — with corroborating findings in humans with lupus and autoimmune liver disease.³⁰ Lupus nephritis has been linked to blooms of a specific gut commensal,³¹ arthritis models point to zonulin and the barrier as a pre-clinical intervention target,²² relapsing-remitting MS shows altered permeability,²¹ and ankylosing spondylitis features dysbiosis with zonulin upregulation.³³

Even the “gut-first” hypothesis in Parkinson’s disease lives here: pathologic alpha-synuclein can propagate from gut to brain along the vagus nerve in models,²⁸ the microbiome influences Parkinsonian neuroinflammation,²⁹ and the neuroanatomy of early disease is consistent with an intestinal entry point.²⁷

The joints are talking, too

Nowhere is this more visible in daily practice than with joint pain and inflammatory arthritis, including rheumatoid arthritis. The mechanistic link is real — experimentally, targeting zonulin and restoring the intestinal barrier can prevent the onset of arthritis,²² and RA is increasingly understood as a disease with roots in mucosal (gut and other) surfaces. What we see lines up with that: when patients clean up the diet — removing gluten and the biggest inflammatory triggers — their joint pain and stiffness often improve dramatically, sometimes within weeks. When a joint responds to a change on the dinner plate, it is telling us something important about where the inflammation was coming from.

Hashimoto’s, TPO Antibodies, and a “Normal” Thyroid Panel

Consider a common and instructive scenario: a person with a thyroid peroxidase (TPO) antibody around 100, but a normal TSH, free T4, free T3, and reverse T3. It’s tempting to conclude that elevated TPO is nearly universal, and that “normal” hormones settle the matter. Two gentle clarifications are worth making.

First, TPO antibodies are not present in most people. They’re found in a meaningful minority, with prevalence varying by sex, age, ethnicity, iodine exposure, and assay. In the NHANES III U.S. population data, thyroid antibodies were common enough to be familiar but far from universal.²⁴ Second, normal hormone levels don’t negate the antibodies. This is often called euthyroid autoimmune thyroiditis: antibodies can precede any measurable loss of thyroid output, and positive individuals carry a higher long-term risk of progressing to hypothyroidism — a relationship documented in the classic Whickham cohort.²⁵ A normal reverse T3, likewise, does not rule out autoimmune thyroid disease.

Where does the gut come in? Research has identified differences in gut microbial composition and permeability-related markers in some patients with Hashimoto’s,²³ and celiac disease travels with autoimmune thyroid disease more often than chance.²⁶ That does not prove the gut caused this particular patient’s antibodies — nor does an elevated TPO prove a specific food is driving it. A reasonable workup repeats TSH and free T4 over time, confirms the antibody and lab range, considers thyroglobulin antibodies and family history, screens for celiac when appropriate, and evaluates the gut rather than either ignoring the antibody or blaming one food for it. (More in our overview of thyroid disorders.)

Mast Cells & Leaky Gut: A Two-Way Street

Leaky gut and mast cell activation often travel together, and the relationship runs both ways. Mast cells sit just beneath the intestinal lining; when they degranulate, the mediators they release (histamine, tryptase, and others) can loosen tight junctions and heighten pain sensitivity. A more permeable barrier, in turn, exposes those same mast cells to more antigens and microbial products, prompting further activation. This is one reason patients with barrier problems so often report histamine-type symptoms — flushing, hives, food reactivity, headaches, and gut distress that migrates and changes.

The Zonulin Problem

Zonulin is marketed almost everywhere as a direct blood or stool test for “leaky gut.” The underlying biology is legitimate — and the commercial testing has serious limits. Both things are true.

Zonulin was identified by Alessio Fasano’s group as pre-haptoglobin 2, a protein that regulates tight junctions.⁷ But later work showed that several widely used commercial ELISA kits may not actually detect pre-haptoglobin 2 — they appear to cross-react with other structurally related proteins, which is why researchers now speak of “zonulin-family peptides.”⁹ Independent studies have also found that serum zonulin measured by these kits does not consistently correlate with directly measured permeability.¹⁰

How We Actually Measure and Test the Gut

No single test captures mucus integrity, tight-junction function, epithelial damage, microbial translocation, mucosal immunity, and food-antigen responses all at once. Good practice combines a few complementary tools and reads them in context.

Where testing runs out of road: SIFO and parasites

Honesty requires naming the blind spots. Fungal overgrowth (SIFO) is very difficult — often effectively impossible — to confirm with current testing. Parasites are their own frustration: in our experience roughly 20–30% of chronic, treatment-refractory SIBO patients ultimately have a parasitic component, yet even advanced stool testing frequently returns false negatives. Giardia and other protozoa are known to directly reduce barrier function through myosin-light-chain signaling,⁴⁹ so missing them matters. When the standard tests keep coming back clean but the patient isn’t improving, we lean on Autonomic Response Technique (ART), a form of advanced biofeedback, to navigate these complex cases and to spend the patient’s time and money where it’s most likely to help.

A Personal Case Study: When Standard Labs Miss It

I’ll offer myself as an example, because it captures the whole problem in one story. Years ago, while practicing conventional family medicine, I was dealing with fatigue, shortness of breath, and anxiety. On a hunch I looked into gluten and ran the standard workup on myself — the LabCorp celiac markers, endomysial IgA and anti-gliadin antibodies. Everything came back negative. By the conventional playbook, gluten was not my problem. And yet, when I actually removed it, I felt noticeably better.

So I ran the Wheat Zoomer from Vibrant America, a far more granular functional panel — and it told a completely different story:

This is the crux of it: a negative standard celiac test rules out celiac disease — it does not rule out non-celiac wheat reactivity or a leaky barrier. Those are different questions, and the conventional panel only answers one of them. Millions of people are told their gluten workup is “normal” and sent on their way, when a functional look — or simply a well-run elimination trial — would have revealed the real picture.

The Diet Question: Low-FODMAP, Ancestral, and Carnivore

Here is perhaps the most persuasive everyday argument that the gut barrier is more than a theory. If “leaky gut” were pure fiction, why do so many patients feel dramatically better within days to weeks simply by changing what they eat — lowering fermentable carbohydrates, cutting grains, and removing inflammatory plant compounds? A concept with no biological reality does not usually respond that fast, that reproducibly, to a fork.

The best-studied version of this is the low-FODMAP diet, which reduces the fermentable carbohydrates that feed gas production and symptoms. In a network meta-analysis it ranked first among dietary strategies for global IBS symptoms,⁶² and the mechanism is well characterized: lower fermentable intake means less colonic gas and symptom genesis.⁴⁵ Grains add a second layer. Beyond gluten and true celiac disease, wheat amylase-trypsin inhibitors (ATIs) can activate the innate immune system through TLR4, driving intestinal inflammation⁶³ — a plausible reason some people feel better off wheat even without celiac disease. (See also our note on lectin sensitivity.)

The ancestral, meat-forward direction

Many of our patients do best on a meat-forward, low-FODMAP pattern — and some of the most striking turnarounds we see come from going further still, toward a largely carnivore, ancestral way of eating that resembles how humans ate for much of our history. When patients shift to mostly animal foods, we have repeatedly observed meaningful improvements in gut symptoms and autoimmune flares. This dovetails with our broader work on low-carb, high-fat eating and insulin resistance.

Voices like Dr. Ken Berry, MD have popularized the observation that many autoimmune conditions improve on a carnivore approach — see, for example, his talk “10 Autoimmune Conditions That Benefit from a Carnivore Diet.” We share that clinical optimism while being candid that rigorous trials are still lacking. The honest framing — and the one most useful to you — is this: a targeted, temporary reduction of fermentable and inflammatory foods is one of the fastest, safest experiments we can run, and your individual response is the data that matters most.

Why elimination works — and why food-allergy testing so often disappoints

This is also, we believe, why elimination consistently outperforms endless testing. Many people spend thousands of dollars on food-allergy and food-sensitivity panels chasing a list of “bad foods,” when the underlying problem was a leaky barrier all along. Remember the mechanism: when the gut leaks, the immune system samples proteins it should have tolerated, so the reactive-food list grows as long as the barrier stays open. Testing that moment in time just photographs the symptom. Heal the barrier and remove the biggest triggers, and the list characteristically shrinks — which is exactly what we see when patients move to a structured elimination, a meat-forward low-FODMAP pattern, or, for some, a carnivore trial: a drastic reduction in food reactions. The fix was never another test; it was the terrain.

Advanced Therapies for Repairing the Gut Lining

Here is where the last few years have genuinely changed what we can offer. When there’s a known cause, treating it is always the most evidence-based move — gluten avoidance in celiac, controlling inflammation in IBD, treating infections, cutting unnecessary NSAIDs, improving glucose control, reducing harmful alcohol, and correcting motility or bile-acid problems that feed overgrowth. But alongside that, we now have targeted tools that have dramatically helped our patients rebuild the barrier. We deploy them in a deliberate order — this is a delicate process, and you cannot simply throw probiotics at the problem.

Peptides: a new frontier in gut repair

Several regenerative peptides show real promise for the gut lining. Larazotide acetate is a tight-junction regulator (a zonulin-pathway antagonist) that reached advanced clinical trials in celiac disease; it showed benefit in earlier-phase studies, though a later phase 3 trial did not meet its primary endpoint — so we frame it as promising, not proven.⁴¹ BPC-157 (a gastric pentadecapeptide) and KPV (an anti-inflammatory alpha-MSH fragment) have compelling preclinical data for healing and calming the gut, but human trials are limited — honest framing matters here.^42,43 Rather than juggle several separate products, these can be combined into a single compounded tablet taken twice daily.

Phosphatidylcholine: rebuilding the membrane itself

Cell membranes — including those lining the gut — are built largely from phosphatidylcholine (PC). PC is also a key component of the protective mucus layer; delayed-release PC has been studied in ulcerative colitis with encouraging results.⁴⁴ Liposomal and high-quality oral PC support membrane repair from the inside out, and pair naturally with our broader membrane-and-detox work.

Butyrate: feeding the lining directly

As covered above, butyrate is the gut lining’s preferred fuel and a direct promoter of tight-junction assembly,³⁵ and it’s frequently depleted in IBS and leaky-gut patients.³⁶ Restoring healthy butyrate levels — conveniently, via tributyrin, a stable, well-absorbed form — goes a long way toward repairing the barrier and improving food tolerance.

Amino acids: the raw materials for the lining and its mucus

The gut lining and its protective mucus blanket are literally built from amino acids, so supplying the right ones is foundational. L-glutamine is the star: it fuels enterocytes and helps preserve tight junctions,³⁴ and in a randomized, placebo-controlled trial, oral glutamine (5 g three times daily) markedly improved symptoms and measured intestinal permeability in post-infectious IBS.⁶⁶ But glutamine is only part of the story. The mucus layer itself is made largely of mucin, and mucin’s backbone is rich in L-threonine, L-serine, L-proline, and L-cysteine — supplying these specific amino acids has been shown to increase mucin synthesis and help restore the mucosal barrier.⁶⁷ Pairing them with dairy-free immunoglobulins (serum-derived, like ImmunoLin) adds a second mechanism: those immunoglobulins bind luminal bacterial fragments such as LPS, lowering the antigen load the barrier has to contend with.⁶⁸

The supportive cast — and the right sequence

Around those cornerstones, several more agents have real mechanistic and clinical support: zinc (including zinc-carnosine) has been shown to tighten a leaky barrier and stimulate repair;^37,38 vitamin D supports barrier integrity via its receptor;³⁹ and anti-inflammatories like curcumin/turmeric⁴⁸ and vitamin C help lower the inflammatory tone. None of these is a proven universal “gut-sealing” cure — but used in the right patient at the right time, they add up.

Sequence is everything. Throwing probiotics at an inflamed, overgrown gut can backfire; probiotics themselves have modest but real barrier benefits across trials,⁴⁰ yet timing determines whether they help. Our general order of operations:

Weighing It Honestly: The Case For and Against

A level-headed article should be able to argue both sides. Here they are, fairly.

These skeptical points don’t disprove barrier dysfunction. They argue for better terminology, better testing, and better clinical reasoning — which is exactly the point.

A More Accurate Clinical Framework

Instead of asking “Does this patient have leaky gut?” we find better questions get better answers:

• Is there evidence of intestinal inflammation or epithelial injury?
• Is there a recognized condition associated with impaired barrier function?
• Are the symptoms more consistent with fermentation, allergy, inflammation, dysmotility, malabsorption, or visceral hypersensitivity?
• Are there medications or exposures (NSAIDs, alcohol, high glucose) impairing the barrier?
• Have we excluded celiac, IBD, infection, pancreatic or bile-acid dysfunction, and immunodeficiency?
• Is overgrowth present — and what keeps predisposing to it?
• Would the proposed test actually change management?
• Is any dietary restriction targeted, time-limited, and followed by reintroduction?
• Are we monitoring objective outcomes rather than just repeating panels?

This preserves the value of functional, systems-based thinking without collapsing every abnormality into a single grand theory.

Your Leaky Gut Action Plan

If this article describes you, here is a sensible, ordered way to begin. This is educational, not medical advice — please partner with your own clinician, especially if you have a diagnosed condition or take medication. But these are the steps we would generally start with.

Frequently Asked Questions